Juno Therapeutics - About the company
Juno Therapeutics is an acquired company based in Seattle (United States), founded in 2013. It operates as a Global biopharmaceutical company discovering, developing, and delivering innovative medicines. Juno Therapeutics has raised $317M in funding. The company has 1228 active competitors, including 69 funded and 150 that have exited. Its top competitors include companies like Amgen, AbbVie and Gilead.
Company Details
Global biopharmaceutical company discovering, developing, and delivering innovative medicines. Focused on cutting-edge science and research, the company develops a multitude of treatment modalities. It offers resources for patients, caregivers, and healthcare providers, including medical information, clinical trials, and patient support programs. The company is committed to global inclusion and diversity, making a positive impact on communities worldwide. It fosters partnerships and collaborations to accelerate the development of new medicines. The company focuses on areas such as immunology, oncology, and other serious diseases. It is dedicated to improving patient outcomes and transforming lives through science. The company also provides resources for investors and media, including financial reporting, press releases, and corporate information.
- Website
- junotherapeutics.com
- Social
Key Metrics
Founded Year
2013
Location
Seattle, United States
Stage
Acquired
Total Funding
$317M in 5 rounds
Latest Funding Round
Investors
Ranked
7th among 1228 active competitors
Annual Revenue
$112M as on Dec 31, 2017
Employee Count
93 as on Mar 31, 2026
Investment & Acquisitions
Exit Details
Acquired by TQ Therapeutics (May 28, 2025)
Legal entities associated with Juno Therapeutics
Juno Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Juno Therapeutics, Inc. CIN: 1594864 , United States, Active | Aug 04, 2013 | $112M (As on Dec 31, 2017) | 730 (As on Dec 31, 2022) | - |
Juno Therapeutics's acquisition details
Juno Therapeutics got acquired by TQ Therapeutics on May 28, 2025.
Click here to take a look at Juno Therapeutics's acquisition in detail
Sign up to download Juno Therapeutics' company profile
Juno Therapeutics's funding and investors
Juno Therapeutics has raised a total funding of $317M over 5 rounds. Its first funding round was on Dec 26, 2013. Juno Therapeutics has 16 institutional investors.
Here is the list of recent funding rounds of Juno Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 05, 2017 | 4047033 | Post IPO | 2992695 | 2402060 | 9320512 | 3712326 |
Jun 29, 2017 | 3891032 | Post IPO | 2862206 | 3146953 | 6209017 | 6116510 |
Aug 14, 2014 | 7950577 | Series B | 7945307 | 8720052 | 7296884 | 1969053 |
Access funding benchmarks and valuations. Sign up today!View details of Juno Therapeutics's funding rounds and investors
Juno Therapeutics' founders and board of directors
Founder? Claim ProfileJuno Therapeutics' employee count trend
Juno Therapeutics has 93 employees as of Mar 26. Here is Juno Therapeutics's employee count trend over the years:
Uncover Juno Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Juno Therapeutics's Competitors and alternates
Top competitors of Juno Therapeutics include Amgen, AbbVie and Gilead. Here is the list of Top 10 competitors of Juno Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 83/100 | |
2nd | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 81/100 | |
3rd | Gilead 1987, Foster City (United States), Public | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 81/100 | |
4th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 80/100 | |
5th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 78/100 | |
6th |  Pfizer 1849, New York City (United States), Public | Provider of pharmaceutical products for multiple disease treatments | - | 77/100 | |
7th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
8th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 71/100 | |
9th | Novartis 1996, Basel (Switzerland), Public | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 70/100 | |
10th |  Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Juno Therapeutics's competitors? Click here to see the top ones
Juno Therapeutics's Investments and acquisitions
Juno Therapeutics has made 2 investments in companies including JW Therapeutics and Editas Medicine. Juno Therapeutics has also acquired 4 companies including AbVitro and XBody.Here is the list of investments & acquisitions:Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Mar 07, 2018 | Investments | 2016 | Shanghai (China) | |
Jan 11, 2016 | Acquisition | 2012 | Boston (United States) | |
Jun 02, 2015 | Acquisition | 2010 | Gyor (Hungary) |
Want to know more about where corporates are investing? Sign up today!See all acquisitions by Juno Therapeutics
Reports related to Juno Therapeutics
Here is the latest report on Juno Therapeutics's sector:
News related to Juno Therapeutics
Filter this list•
Oxford BioMedica shares up on deal expansion in CAR-TMorningstar•Jul 21, 2022•Oxford BioMedica, Juno Therapeutics
•
•
•
Secretive Seattle biotech company raises more than $700M to develop new ways to modify genesGeekWire•Jun 23, 2020•Sana Biotechnology, Arch Venture Partners, Flagship Pioneering, CPP Investments and 10 others
•
Chinese biopharma firm JW Therapeutics nets $100m in Series B round led by CPE, Mirae AssetDeal Street Asia•Jun 10, 2020•JW Therapeutics, Mirae Asset Global Investments, Citic PE, WuXi AppTec and 10 others
•
•
Jury awards BMS subsidiary $752M in CAR-T patent infringement suitMedCity News•Dec 15, 2019•Kite Pharma, Juno Therapeutics
•
Jury orders Gilead's Kite Pharma to pay $752M for CAR-T patent infringementFiercepharma•Dec 13, 2019•Bristol-Myers Squibb, Gilead, Juno Therapeutics
•
Editas and Celgene sub Juno are tackling hottest immunotherapy cellsEndPoints News•Nov 12, 2019•Celgene, Juno Therapeutics, Editas Medicine
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Juno Therapeutics
Explore our recently published companies
- Zazen Health Solutions - Petaling Jaya based, 2006 founded, Unfunded company
- SURFLOFT - Petaling Jaya based, 2008 founded, Unfunded company
- Eaglewood School - New Milton based, Unfunded company
- Friskney Primary - Boston based, Unfunded company
- Royce City ISD - Royse City based, Unfunded company
- Markets Web Services - Dauphin based, Unfunded company
